Microfibrils are found in the extracellular matrices of most tissues where they serve several functional roles, including the binding and sequestration of growth factors, supplying informational signals through receptor signaling, and providing the basic structural elements for elastic fiber assembly. Many different proteins have been localized to microfibrils, although it is not clear whether all are structural proteins or proteins that simply associate with other components of microfibrils (1, 2).
Microfibrils are found in the extracellular matrices of most tissues where they serve several functional roles, including the binding and sequestration of growth factors, supplying informational signals through receptor signaling, and providing the basic structural elements for elastic fiber assembly. Many different proteins have been localized to microfibrils, although it is not clear whether all are structural proteins or proteins that simply associate with other components of microfibrils (1, 2) .
The fibrillins provide the basic functional framework of microfibrils. This multigene family consists of three related proteins (fibrillin-1, -2, and -3) that have a similar domain structure but differ in expression pattern and biological function (3) . The fibrillins are secreted from the cell as dimers that then pack together in ways that are not completely understood to form the microfibril. Extracted microfibrils are typically visualized as a linear string of beads with multiple arms extending into the interbead region. The beads show a ϳ50-nm spacing, and several models of fibrillin assembly have been proposed to account for packing a 150-nm fibrillin monomer into a structure with 50-nm periodicity (4, 5) .
A second protein associated with microfibrils is a small molecular mass glycoprotein called microfibril-associated glycoprotein. MAGP-1 1 contains 183 amino acids that form two distinctive domains; the N-terminal half of the molecule is highly acidic, enriched in proline, and contains a clustering of glutamine residues, whereas the C-terminal portion contains all 13 cysteine residues and contains the matrix-binding domain that mediates the association of MAGP-1 with microfibrillar components (6) . The protein undergoes post-translational transglutamination, sulfation of specific tyrosine residues, and O-linked glycosylation (7) . In mouse development, MAGP-1 mRNA is widely expressed, mainly in mesenchymal and connective tissue cells where it is easily detected as early as day 8.5 of development (8) . MAGP-1 is associated with all microfibrils with only two known exceptions: those directly adjacent to the plasma membrane of aortic endothelial cells and those at the junction of the zonule and the lens capsule of the eye (9 -11) .
MAGP-2 is a second member of the MAGP family that has close sequence similarity to MAGP-1 in a central region of 60 amino acids, where the spacing of 7 cysteine residues is identical in both proteins. The MAGP-2 molecule is otherwise rich in serine and threonine residues and lacks the proline-, glutamine-, and tyrosine-rich sequences characteristic of the Nterminal domain of MAGP-1 (12) (13) (14) (15) . MAGP-2 exhibits a more restricted pattern of tissue localization and developmental expression than MAGP-1 (15) , suggesting that MAGP-1 and MAGP-2 are structurally divergent proteins sharing one functional motif (encoded by two conserved exons) rather than being functionally closely related molecules. Both MAGPs have been shown to directly bind to purified fibrillin, and for MAGP-2, a prominent binding site was localized to a C-terminal region of fibrillin-1 containing seven tandem calcium-binding EGF-like repeats (16) . Preliminary mapping studies with MAGP-1 have localized putative binding sites near the N terminus (17) and in the middle portion (18) of fibrillin-2, although these sites have not been mapped in great detail.
In this study, we used a biochemical and molecular approach to precisely identify a prominent MAGP-1-binding site in fibrillin-2. The binding site maps to an 8-cysteine motif, encoded by exon 24, in a region of the fibrillin-2 molecule where mutations associated with the inherited disease congenital contractural arachnodactyly cluster. This is also the region where mutations in fibrillin-1 produce the most severe form of Marfan syndrome. Because MAGP-1 has been shown to reside on the bead structure of microfibrils (9) , defining its binding site in fibrillin is important in discerning which part of the fibrillin molecule contributes to the bead. This information is critical for understanding the molecular packing that facilitates fibrillin assembly into a microfibril.
EXPERIMENTAL PROCEDURES
Materials-A partial FBN2 cDNA was provided by Dr. Francesco Ramirez (Hospital for Special Surgery at Weill Medical College of Cornell University, Ithaca, NY). A bovine MAGP-1 cDNA was provided by Dr. Mark Gibson (University of Adelaide, Adelaide, Australia), and the human MAGP-1 cDNA is described in Segade et al. (6) . Murine macrophage elastase was provided by Dr. Steven Shapiro (Harvard University, Boston, MA). Cell culture media and supplies were from commercial suppliers as indicated or from the Washington University Tissue Culture Support Center. The Matchmaker GAL4 Two-hybrid System 3 was purchased from Clontech. Restriction endonucleases and other enzymes were purchased from Promega or Roche Applied Science. All other reagents were obtained from Sigma, Fisher, and Bio-Rad unless noted.
Yeast Two-hybrid Assay-FBN2 constructs were subcloned into the pGADT7 yeast expression vector (Clontech) encoding the GAL4 activation domain. The DNA fragment coding for the MAGP-1-MBD (exons 7-8) was amplified from the MAGP-1Ex(7-8)-GFP expression vector (6) and subcloned into the yeast expression vector pGBKT7 (Clontech), coding for the GAL4 DNA-binding domain. pGADT7-FBN2 plasmids (500 ng) and pGBKT7-MAGP-1Ex(7-8) plasmid (1000 ng) were used to co-transform Saccharomyces cerevisiae AH109 cells following the manufacturer's instructions. To assess transformation efficiency, transformation mixtures were plated on the nutritionally selective medium SDϪLeu/ϪTrp; and to select for GAL4-dependent growth, transformed cells were plated on the nutritionally selective medium SDϪAde/ϪHis/ ϪTrp/ϪLeu. The plates were incubated at 30°C for 4 -6 days. The colonies were scanned and counted by IPLAB software, version 3.53 (Scanalytics Inc.). The colony number is expressed as the quotient between the number of colonies in the SDϪAde/ϪHis/ϪTrp/ϪLeu medium divided by the number of colonies in SDϪLeu/ϪTrp medium, and then expressed as a percentage of the values obtained from the positive control (co-transformation of plasmids pGADT7-T and pGBKT7-p53 encoding the interacting partners SV40 Large T antigen and human p53 proteins, respectively). Transformations with each of the expression vectors alone or in combination with the empty pGBKT7 vector (for FBN2 constructs) or empty pGADT7 vector (for the MAGP-1-MBD construct) were used as negative controls. ␣-Galactosidase activity (MEL1) was assayed as described by Ryan et al. (19) .
In Vitro Translation Procedures-[ 35 S]Cys-labeled FBN2 protein fragments were prepared by in vitro transcription/translation of the plasmids used in the Y2H study using TNT coupled reticulocyte lysate system as described by the manufacturer (Promega). The ability of the radiolabeled peptides to bind bacterially expressed GST-MAGP1Ex (7) (8) was assessed by ligand blot followed by autoradiography. Antibodies-Antibodies to Aik (the region of FBN2 encoded by exons 10 -17), MAGP-1, and NLR3 have been described (7, 18, 20) . Polyclonal antibody to fibrillin-2 exon 24 was generated against the bacterially expressed exon 24 fusion protein described above.
Plasmid Constructs-Construction of the full-length bovine MAGP-1 expression vector in pEE14 is described in Trask et al. (7) . The NLR3e/6 and Aik mammalian expression constructs are described in Trask et al. (20) . For the generation of FBN2 deletion mutants (Fig. 1) , 2 the appropriate oligonucleotide primers were used in high fidelity PCR using Pfu Turbo polymerase (Stratagene, La Jolla, CA) to amplify DNA fragments derived from human FBN2 (GenBank TM /EBI accession number U03272) cDNA sequences. Amplified constructs were cloned into the appropriate expression vector as indicated in the main text. The integrity of the constructs was verified by sequencing. Plasmids for transfections were purified from bacterial cultures using the Qiagen EndoFree DNA purification kit.
Production of FBN2 Fragments in Bacterial Cells-For the expression of FBN2 truncation products in bacteria, the amplified coding fragments were cloned into the appropriate pQE series of isopropyl-␤-D-thiogalactopyranoside-inducible vectors (Qiagen) to obtain a fusion product with a N-terminal 6-histidine tag. For large scale production of recombinant proteins, log phase cells cultured in 100 ml of Luria broth at 37°C were induced to produce protein with 1 mM isopropyl-␤-Dthiogalactopyranoside. Five hours post-induction, the cultures were pelleted, lysed with lysis buffer containing 100 mM NaH 2 PO 4 , 10 mM Tris, and 8 M urea, pH 8.0, and centrifuged at 12,000 ϫ g for 20 min. Recombinant proteins were purified from the crude lysate by binding to Ni 2ϩ -nitrilotriacetic acid agarose matrix (Qiagen). After two washes with urea buffer adjusted to pH 6.3, the retained FBN2 proteins were eluted from the resin with buffer containing 100 mM NaH 2 PO 4 , 10 mM Tris, and 8 M urea, pH 5.9.
Production of MAGP-1 and FBN2 Fragments in Mammalian CellsThe generation of CHOK1 stable transfectants expressing NLR3e/6, Aik, and full-length bovine MAGP-1 and the protein purification procedures are described elsewhere (18, 20) .
Production of FBN2 Fragments in Sf9 Insect Cells-To express the fragment FBN2Ex (18 -25) , the amplified coding sequence was cloned into the pFastBac shuttle vector (Invitrogen). After plasmid/bacmid recombination, positive clones were identified by blue/white selection. Bacmid DNA was prepared by alkaline lysis and transfected into Sf9 cells in serum-free medium using Lipofectin (Invitrogen) for 4 h at 27°C. After cell lysis, which occurred about 5 days after transfection, the conditioned medium was removed, centrifuged to eliminate cell debris, and used to infect fresh Sf9 cultures. Positive cultures for protein expression were determined by Western blot of Ni 2ϩ -nitrilotriacetic acid-agarose-purified conditioned medium.
SDS-PAGE and Western Blot Analysis-
The proteins were resolved by SDS-PAGE in polyacrylamide gels. For reducing gels, 50 mM dithiothreitol was added to the sample buffer. After electrophoresis, the proteins were transferred from gels to nitrocellulose membranes (Schleicher & Schuell) for 1 h at 70 V in 10 mM 3-[cyclohexylamino]-1-propanesulfonic acid, 10% methanol (v/v). For Western blot analysis, the membranes were blocked with 5% (w/v) nonfat dry milk, 0.1% Tween 20 in phosphate-buffered saline for 1 h at 37°C, then incubated with specific primary antibodies (1:1000) for 1 h, and washed twice with blocking agent. The membranes were incubated with a 1:1000 dilution of a peroxidase-linked donkey anti-rabbit IgG (Amersham Biosciences) in blocking buffer for 1 h, washed twice, and developed with the ECL system (Amersham Biosciences) according to the manufacturer's instructions.
Ligand Blot Analysis-FBN2 constructs were run on 10 -15% SDS-PAGE gels under either reducing or nonreducing conditions and transferred to nitrocellulose as described above. The blots were blocked after transfer with 5% (w/v) nonfat milk and 0.1% Tween 20 in phosphatebuffered saline (blocking agent) for 1 h at room temperature. Fulllength bovine MAGP-1 partially purified by QA-cellulose chromatography was added to the blocking agent, and the blots were incubated for 90 min at 37°C under gentle shaking. The blots were washed and then incubated with MAGP-GST antibody diluted 1:1000 in blocking agent for 1 h at 37°C. Bound protein was detected with horseradish peroxidase-coupled donkey anti-rabbit IgG (Amersham Biosciences) diluted 1:1000 in blocking agent for 1 h at 37°C. The blots were then washed three more times with milk/phosphate-buffered saline, and the immunoreactive proteins were visualized with the ECL system. Autoradiography was used to detect bound, radiolabeled proteins generated by in vitro translation.
Solid Phase Binding Assay-Fibrillin-2 constructs expressed in CHO cells were isolated from culture medium using ammonium sulfate precipitation or nickel affinity chromatography. The proteins were suspended in Tris-buffered saline and added to wells of 96-well plates. After 16 h at 4°C, the wells were rinsed three times with wash buffer consisting of Tris-buffered saline containing 2 mM CaCl 2 and 0.05% (v/v) Tween 20, and nonspecific binding sites were blocked with 5% (w/v) nonfat dry milk in Tris-buffered saline, 2 mM CaCl 2 (binding buffer) for 1 h at room temperature. After three washes with wash buffer, the fibrillin-coated wells were incubated for 2 h at 37°C with serial dilutions of MAGP-1-containing medium harvested from MAGP-1-transfected CHO cells. At the end of the incubation period, the wells were washed three times with wash buffer and incubated for 1 h with an antibody to MAGP-1 diluted 1:500 in binding buffer. After three washes, the wells were incubated 1 h with a peroxidase-conjugated goat anti-rabbit immunoglobulin (1:500 dilution) and washed, and bound antibody was detected with the ABTS Microwell Peroxidase Substrate System as described by the manufacturer (KPL Laboratories).
Bioinformatics-Primary sequence input, alignment, and conceptual translation were performed with the LASERGENE package of programs (DNASTAR, Inc., Madison, WI).
RESULTS

The Matrix-binding Domain in MAGP-1 Binds to the Nterminal Region of FBN2-
To map the MAGP-1-binding site in fibrillin-2, we utilized yeast two-hybrid assays to identify associations between fragments of fibrillin-2 and the MAGP-1-MBD. The MBD of MAGP-1, a cysteine-rich region encoded by exons 7 and 8, was shown in earlier studies to be the minimal sequence in MAGP-1 capable of directing its deposition onto microfibrils in the extracellular matrix (6) . The functional constructs consisted of the MAGP-1-MBD cloned into the pGBKT7 yeast expression vector coding for the GAL4 DNA-binding domain to generate a fusion protein GAL4 BD-MBD that served as bait. Constructs derived from the Nterminal region of FBN2 were cloned into the pGADT7 vector that codes for the GAL4 activation domain to generate FBN2-GAL4 AD chimeric proteins that were used as targets. The ability of each construct to make appropriate protein was verified by in vitro translation, as described below. Yeast competent cells were co-transformed with the MAGP-1 plasmid bait and a FBN2 target vector, and selection was performed by culture of the transformed cells in triple selective medium (see "Experimental Procedures") that restricts growth to those cells in which interaction between bait and target takes place. To minimize the number of false positives, we measured the GAL4-dependent ␣-galactosidase activity.
As shown in Fig. 2 and summarized in Table I , no functional interaction was detected between the MAGP-1-MBD and FBN2Ex(1-9) or FBN2Ex(58 -63). GAL4-dependent cell growth (Fig. 2) and ␣-galactosidase activity (Table I) (Table I and Fig. 2 ). Interestingly, no interaction was detected when the MBD was screened against exon 24 alone (FBN2Ex24) or exon 23 alone (FBN2Ex23), suggesting that the MAGP-1-MBD does not interact with exon 24 in the Y2H assay without a flanking EGF domain.
Yeast Two-hybrid Results Confirmed by Ligand Blot Analysis-To corroborate the Y2H results, we utilized a ligand blot assay in which protein from the FBN2 constructs generated by in vitro translation was probed with bacterially expressed GST-MAGP-1Ex (7) (8) . We took advantage of the presence of the T7 promoter in the pGADT7 vector used to clone the FBN2 fragments to generate transcripts that were in vitro translated using reticulocyte lysate containing [
35 S]cysteine. Integrity of the proteins and confirmation of their predicted molecular masses were done by electrophoresis in denaturing gels followed by autoradiography (not shown). For the ligand blot, the GST-MAGP-1Ex(7-8) protein was separated using 10% polyacrylamide gels, transferred to nitrocellulose, and incubated with individual in vitro translated FBN2 fragments. After washing, bound fragment was detected by autoradiography. A summary of the results, shown in the right column of Table I , confirmed the interactions detected by Y2H.
MAGP-1 Binds to the N-terminal Region of FBN2-
The Y2H experiments provided information suggesting that the binding domain for MAGP-1 is located in exons 18 -25 of fibrillin-2 but were not definitive in identifying the precise binding sequence in this region. To better characterize the MAGP-fibrillin-2 interaction, we used full-length MAGP-1 protein in ligand blot assays with a recombinant fragment of FBN2 encoded by exons 1-25, FBN2Ex(1-25), described in previous studies as NLR3e/6 (21). Both proteins were expressed in CHO cells and purified from the conditioned media as described under "Experimental Procedures." Fig. 3A shows purified FBN2Ex(1-25) protein (predicted molecular mass, ϳ118,000) separated using 10% polyacrylamide-SDS gels and stained with Coomassie Blue to verify purity. Tropoelastin was included as a positive control for the ligand blot assay because its interaction with MAGP-1 has been previously described (22) . Ovalbumin served as a control for nonspecific interactions. For ligand blot analysis, the proteins were transferred to nitrocellulose and incubated with purified full-length bovine MAGP-1. Anti-MAGP-1 antibodies were then used to detect MAGP-1 bound to the immobilized proteins. Fig. 3B shows that MAGP-1 bound to both tropoelastin and FBN2Ex(1-25), but no interaction was detected with the negative control protein, ovalbumin. FBN2Ex(1-25) construct, purified FBN2Ex(1-25) protein was digested with mouse macrophage elastase (MMP-12), a metalloprotease that cleaves FBN2 at a single site within the glycine-rich domain (exon 10) (23). Fig. 4A shows that MMP-12 cleavage generated two fragments of ϳ85 and ϳ45 kDa. A small amount of undigested FBN2Ex(1-25) was also visible. Western blotting with an antibody to exon 24 confirmed that the larger fragment (ϳ85 kDa) contained the C-terminal portion of FBN2Ex(1-25) (not shown) and, hence, contains exons 10 -25. Evidence that the higher molecular mass band is not a dimer of the 45-kDa protein was demonstrated using an antibody generated against a peptide sequence in exon 1 of fibrillin-2. Only the parent protein and lower band were positive with this antibody (not shown). After transfer to nitrocellulose, incubation with full-length MAGP-1 and detection with the MAGP-1 antibody showed an interaction between MAGP-1 and the intact, undigested FBN2Ex(1-25) protein as well as the 85-kDa cleavage product (Fig. 4B ). There was no interaction of MAGP-1 with the ϳ45-kDa fragment, which contains the Nterminal sequences encoded by exons 1-9. It is important to note that MAGP-1 bound efficiently to reduced FBN2Ex(1-25) (Fig. 4B) , indicating that binding is independent of the oxidation state of the disulfide bonds. To confirm that the lack of interaction between MAGP-1 and the 45-kDa digestion product was not due to the proteolysis of specific determinants as a result of mouse macrophage elastase treatment, we generated a plasmid construct (NLR3c) containing exons 1-9 of FBN2. The protein product, FBN2Ex(1-9), was expressed in bacteria, affinity-purified by Ni 2ϩ -nitrilotriacetic acid-agarose chromatography, and used in a ligand blot assay. Consistent with results from the MMP-12 digest and Y2H assays, we were not able to detect an interaction between FBN2Ex(1-9) and MAGP-1 (Fig. 4C) , confirming the absence of a MAGP-1-binding site in the N-terminal region of fibrillin-2 protein.
Mapping of the Interaction of FBN2 and MAGP-1 to Exons 10 -25 of FBN2-To better localize MAGP-1 binding within the
TABLE I Summary of yeast two-hybrid and cell-free translation ligand blotting results assessing the interactions between fragments of fibrillin-2 and the MAGP-1 matrix-binding domain
Ex 10-17 3ϩ ϩ ϩ Ex 16-17 2ϩ ϩ ϩ Ex 18-25 4ϩ ϩ ϩ Ex 18-20 4ϩ ϩ ϩ Ex 20 3ϩ ϩ ϩ Ex 20-23 4ϩ ϩ ϩ Ex23-25 4ϩ ϩ ϩ Ex 23-24 4ϩ ϩ ϩ Ex 23 Ϫ Ϫ Ex 24 Ϫ Ϫ Ex 37-38 Ϫ Ϫ Ex 58
Mapping of the MAGP-1-binding Domain to FBN2 Exon 24 -Y2H
and ligand blot analysis both confirm that MAGP-1 binds fibrillin-2 at a site between exons 10 and 25. To define the sequence required for the MAGP-1-FBN2 interaction, we developed a series of expression constructs that span the FBN2Ex(10 -25) region. The first construct, expressed in CHO cells from the Aik plasmid (21) , produced the FBN2Ex(10 -16) fragment (Fig. 1) . In ligand blot assays, MAGP-1 was unable to bind the FBN2Ex(10 -16) protein (Fig. 5) , thus indicating that the MAGP-1-binding site is located between exons 18 and 25.
This region of the molecule, FBN2Ex (18 -25) , was cloned into a baculovirus expression vector and expressed in Sf9 insect cells (Fig. 6A) . Western blot analysis indicated that the recombinant protein was intact after purification. Ligand blotting confirmed that the MAGP-1-binding site was active in this smaller fragment of FBN2 (Fig. 6) , consistent with the Y2H results. Constructs coding for the front FBN2Ex (18 -22) and back Ex (23) (24) (25) halves of the active region were then expressed in bacterial cells, and the purified recombinant proteins were assayed by ligand blot. Fig. 6B shows that only FBN2Ex (23) (24) (25) retained the ability to bind full-length MAGP-1. To assess whether the EGF domains that flank exon 24 in FBN2Ex (23) (24) (25) are required for its binding to MAGP-1, as was found in the yeast two-hybrid assay, we utilized an expression construct that encoded just Ex24. Ligand blot of bacterially expressed protein demonstrated that exon 24 retains the ability to bind MAGP-1 (Fig. 7) without the presence of EGF-flanking domains. A second 8-cysteine domain, encoded by exons 37-38, located outside the MAGP-1-binding region, was negative in the ligand blot assay (Fig. 7) , confirming that MAGP-1 does not interact nonspecifically with these unique sequences. Together, the Y2H and ligand blot analysis indicate that the MAGP-1-binding domain is located within exon 24 of fibrillin-2.
The ability of exon 24 to bind MAGP-1 was also assessed using solid phase binding assays. Fig. 8 shows that full-length MAGP-1 bound strongly to immobilized FBN2Ex24 and FBN2Ex , whereas the fragment FBN2Ex(1-9) did not show binding activity. These results confirm the exon 24-binding site and provide further evidence for the absence of a MAGP-1 interactive domain in the N-terminal region of the fibrillin molecule.
DISCUSSION
In this study, we used Y2H, ligand blotting techniques, and solid phase binding assays as separate and confirmatory experimental approaches to map the MAGP-1-binding site in fibril- lin-2. Y2H has been used by several laboratories to document interactions between other extracellular matrix proteins, including type IV collagen (24) , thrombospondin 1, the laminin ␤3 chain, and the NC1 domain of type VII collagen (25) , as well as the microfibrillar protein emilin (26) and MAGP-2 (16). In our assays, Y2H provided a useful way to screen potential binding sites but was not sufficiently precise to unambiguously identify the correct binding sequence. Although the clone containing the correct MAGP-1-binding subdomain was one of positive constructs identified with Y2H, its specific binding properties were only apparent after validation by other techniques.
Y2H could not be used with full-length MAGP-1 as bait because MAGP-1 has the propensity to aggregate and selfactivate in the two-hybrid assay, producing many false positives. This problem was circumvented by using only the matrixbinding domain of MAGP-1 as bait, which remained soluble in the Y2H assays and was able to identify three MAGP-1 binding sequences in fibrillin-2: exons 16 and 17, exon 20, and exons 23 and 24. Ligand blots with full-length MAGP-1 narrowed the site of interaction to the 8-cysteine domain in exon 24. Other 8-cysteine domains were negative in the blot assays, suggesting that there is something unique about exon 24 and its ability to bind MAGP-1.
There are several possible explanations for the subtle differences in binding sites detected by Y2H and the other assay methods. The simplest explanation relates to the different forms of the two proteins used in the assays. The MAGP-1-MBD construct used in the Y2H assays contains only two of the nine exons of MAGP-1 and may be less specific than the fulllength protein used for the ligand blots. Alternatively, weak and transient interactions are more readily detected in twohybrid assays because the genetic reporter gene strategy results in a significant amplification. Hence, this difference in sensitivity and specificity may explain why Y2H gave positive results for exons 16 and 17, exon 20, and exons 23 and 24, whereas ligand blot identified only exon 24. The interaction between the MAGP-1-MBD and exons 16 and 17 and exon 20 may have biological significance that is unrelated to the fulllength MAGP-binding site in exon 24. Several studies have shown that the region between exons 10 and 24 of fibrillin is a site where several extracellular matrix proteins, including tropoelastin and decorin, are known to bind (18, 21) . This suggests that this region may define a matrix-binding domain with multiple binding specificities and affinities.
It is interesting that neither full-length MAGP-1 (ligand blot, solid phase binding assay) or the MAGP-1-MBD (Y2H and cell-free translation) interacted with N-terminal constructs (exons 1-9) that contain sequences shown by Jensen et al. (17) to encode the MAGP-1-binding region in fibrillin-1. The amino acid sequences of fibrillin-1 and -2 are highly homologous through exon 9, except for the N terminus encoded by exon 1 where the sequence is quite different. It is possible that the MAGP-1-binding site is located in exon-1 of fibrillin-1 but is missing from or inactive in, fibrillin-2 because of sequence differences. A MAGP-1-binding site in exon 1 would be compatible with the studies of Jensen et al. (17) , who showed positive MAGP-1 binding to a fibrillin-1 fragment encoding exons 1-11 but negative binding to fragments spanning this region but lacking exons 1-3.
The MAGP-1-MBD was also inactive against the fibrillin-1 C-terminal sequences (exons 58 -63) shown by Penner et al. (16) to bind MAGP-2. Although this result was unexpected given the high sequence homology in the MBDs of MAGP-1 and 2, we have shown in a previous study that the binding specificities of the two sequences are different because of the substitution of a valine for cysteine residue in the MAGP-2 sequence (6). It is not known why this substitution alters the recognition preference of MAGP-2 for EGF-like sequences as opposed to the 8-Cys motif recognized by MAGP-1.
The localization of MAGP-1 binding to the 8-Cys domain encoded by exon 24 has important implications for understanding microfibril assembly. Immunolocalization experiments have demonstrated that fibrillin-1 and -2 can co-polymerize in the same individual microfibril (29, 30) , suggesting that the molecular information directing fibrillin fibril formation must be similar for both fibrillins. Because MAGP-1 has been localized to the bead region of microfibrils, our results would suggest that the bead consists of exon 24 and portions of the central region of fibrillin-2 (and by analogy, the central portion of fibrillin-1).
All of the established models of fibrillin assembly orient fibrillin in a head to tail pattern within the microfibril (4, 5, 31, 32) . There is disagreement, however, on which domains of the fibrillin molecule constitute the bead-like structures seen on extracted microfibrils. Based on antibody mapping studies, Reinhardt et al. (4) proposed that the N-and C-terminal ends of fibrillin-1 are located in proximity and on opposite sides of the beads, and more central parts of the molecule are located between the beads. Baldock et al. It is important to note that exon 24 in fibrillin lies in the region of the molecule where mutations produce the most severe phenotypes associated with Marfan syndrome (fibrillin-1) and congenital contractural arachnodactyly (fibrillin-2). It is possible that these mutations alter the ability of fibrillin to bind MAGP-1, which may contribute to the severity of the disease. What role MAGP-1 plays in microfibril assembly or stabilization, however, awaits further characterization of MAGP-1 function.
